罗非
1.Conclusion:Tirofiban can improve the situation of myocardial reperfusion after PCI in patients with STEMI.
2.Objective:To observe the efficacy and safety of use of platelet glycoprotein Ⅱb/Ⅲa receptor antagonist(tirofiban) in acute coronary syndrome(ACS).
3.The withdrawal is a big blow for Merck, which is already reeling from the failure of two of its most important new medicines in clinical trials.
4.Objective To observe the safety and efficacy ofglycoprotein Ⅱb/Ⅲa receptor inhibitors (tirofiban) in the treatment for acute coronary syndromes.
5.Conclusion The results suggest that Tirofiban is a safe and tolerable therapy drug for ACS(UA/NSTEMI) patients referred to percutaneous coronary intervention,the same as to high risk stratificated patients.
6.Methods The gastric cancer cell line BGC-823 cells were incubated for 48 hours with rofecoxib and celecoxib, 5-Fu, DDP and VP-16 (concentration gradient of 5-Fu, DDP and VP-16:1μg/ml, 10μg/ml and 100μg/ml), or in combination, respectively.
